Innovations in Oncology Learning Center: From Guidelines to Practice—Breast Cancer

10 episodes

1.50 program credits

1h 32m

Details

Episodes

Presenters

Comments

Overview
Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to provide the most accurate recommendations based on recent scientific evidence and drug approvals. This activity has been designed to review the current NCCN guidelines and the supporting data and explore best practices for selecting therapy based on these recommendations.
Explore guideline-based strategies and clinical data to optimize guideline-adherent care for patients with CLL/SLL and MCL.
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
William Gradishar, MD, FASCO
Northwestern University
Chicago, IL
Dr. Gradishar has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting fees:AstraZeneca, Daiichi Sankyo, Genentech, Merck
Erica Mayer, MD, MPH
Dana Farber Cancer Institute
Boston, MA
Dr. Mayer has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting fees: Arvinas, AstraZeneca, Lilly, Novartis
Peter Schmid, MD
Barts Cancer Institute
London, United Kingdom
Dr. Schmid has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: Astellas, AstraZeneca, Genentech, Medivation, Merck, Novartis, OncoGenex, Roche
Consulting fees: AstraZeneca, Bayer, Boehringer Ingelheim, Celgene, Eisai, Merck, Novartis, Pfizer, Puma, Roche
Reviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Wilma Guerra has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Apply evidence-based, guideline-concordant testing and treatment approaches for patients with early-stage breast cancer (EBC)
- Develop evidence- and guideline-based treatment strategies across lines of therapy in metastatic breast cancer (MBC)
- Contextualize emerging data with practice-changing potential to enhance outcomes for patients with EBC and MBC
- Utilize region-specific treatment delivery approaches aligned with NCCN Guidelines for patients with EBC and MBC
Target Audience
This activity has been designed to meet the educational needs of medical oncologists and pathologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with breast cancer.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 contact hour/0.1 CEUs of pharmacy contact hours.

The Universal Activity Number for this program is JA0006235-0000-24-161-H01-P. This learning activity is knowledge based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credit(s). Approval is valid until 12/30/2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., Lilly and Merck Sharp & Dohme LLC.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 12/30/2024
Expiration Date: 12/30/2025

William J. Gradishar, MD

Erica L. Mayer, MD, MPH

Peter Schmid, FRCP, MD, PhD

NCCN Guidelines - Breast Cancer

Title

Share on ReachMD